



P: 734-429-9053 | F: 734-944-3934

968 E Michigan Ave | Saline, MI 48176

Mon - Fri: 9am-6pm | Sat: 9am-3pm | Sun: Closed

# ELECTRONIC PRESCRIBING (E-PRESCRIBING)

## Compounded Semaglutide 1mg-1ml in SubMagna™ HMW

1. Identify *Jensen's Community Pharmacy - Saline* as the Desired Pharmacy in EMR System
  - Phone Number: 734-429-9053
  - Address: 968 E Michigan Ave, Saline, MI 48176
  - NPI: 1093084303
2. Select the medication – Two Options Typically Considered
  - If your EMR system allows you to free-form a compounded medication that does not have a single-number NDC, consider free-form typing "Compounded Semaglutide 1mg-1ml in SubMagna™ HMW" as the prescribed medication.
  - If your EMR system does NOT allow you to free-form a compounded medication, consider selecting RYBELSUS® 14mg Tablet and adding the clarification for the specific medication prescribed in the SIG or Prescription Direction Field as described below in #3.
3. Add the Directions or "SIG" (Use to Embed Compound Name and Compound Directions – Pick One)
  - Option 1: Write into notes: "Compounded Semaglutide Sublingual 13-Week Protocol." This includes the following:
    - 1st fill: Semaglutide 1mg/ml Suspension
      - Place 0.5ml under the tongue for a minimum of 2 minutes once daily for 2 weeks then increase to 1ml once daily. Do not eat or drink anything for 30 minutes after dose
    - 2nd fill: Semaglutide 2mg/ml Suspension
      - Place 1ml under the tongue for a minimum of 2 minutes once daily. Do not eat or drink anything for 30 minutes after dose
    - 3rd fill: Semaglutide 3mg/ml Suspension
      - Place 1ml under the tongue for a minimum of 2 minutes once daily. Do not eat or drink anything for 30 minutes after dose
    - Maintain dosage of 3mg daily thereafter
  - Option 2: Compounded Semaglutide 1mg-1ml in SubMagna™ HMW – Once daily, place \_\_\_\_ml under tongue for a minimum of 2 minutes before swallowing. Do not eat or drink for 30 minutes after taking.
4. Select Quantity in 30ml increments
5. Enter Number of Authorized Refills

RYBELSUS® is a registered trademark of Novo Nordisk A/S. No compounded medication is reviewed by FDA for safety or efficacy. SubMagna™ HMW is a trademark of Kingdom Licensing. Above is general proposed guidance that should be adapted to each individual prescriber's practice setting.

## QUESTIONS? CONTACT US!